Liquidia's third consecutive quarter of profitability and accelerating YUTREPIA sales (44% Q/Q growth) validate the commercial trajectory. The $222.8M cash position funds operations and pipeline expansion without dilution. Key catalysts to watch: L606 Phase 3 Re-Spire enrollment progress, resolution of United Therapeutics litigation (injunction risk), and continued prescription growth trajectory. The stock should re-rate higher given the beat vs consensus and self-funding business model.
Price Chart
Executive Summary
Liquidia Corp reported Q1 2026 results with YUTREPIA net product sales of $129.9M, net income of $52.9M ($0.52 diluted EPS), and adjusted EBITDA of $71.2M — its third consecutive quarter of profitability. The company also updated its corporate presentation highlighting continued commercial momentum with >4,500 patient prescriptions and ~980 prescribers since launch, and advancement of its L606 Phase 3 Re-Spire study.
Key Financial Metrics
Key Facts
- YUTREPIA net product sales of $129.9M in Q1 2026, up 44% Q/Q from $90.1M in Q4 2025
- Net income of $52.9M ($0.52 diluted EPS) vs net loss of $38.4M ($0.45 loss per share) in Q1 2025
- Adjusted EBITDA of $71.2M, up 2.6x from $27.3M in Q4 2025
- Cash and cash equivalents of $222.8M, up $32.1M from $190.7M at year-end 2025
- More than 4,500 unique patient prescriptions and ~3,750 patients treated since launch in June 2025
- Prescriber base grew to more than 980, with ~25% increase in prescribers with 5+ referrals since February
- Actively screening patients for Phase 4 Tyvaso transition study and pivotal Phase 3 Re-Spire study of L606
- Ongoing litigation with United Therapeutics seeking injunctive relief remains a key risk
Financial Impact
Q1 2026 revenue of $132.9M vs consensus $119.4M (beat by ~11.3%); GAAP diluted EPS of $0.52 vs Street consensus of $0.34 (beat by ~52.9%)
Risk Factors
- United Therapeutics litigation seeking injunctive relief could block YUTREPIA sales for PAH and/or PH-ILD
- Competition from Tyvaso/Tyvaso DPI and other inhaled prostacyclins
- Clinical trial risks for L606 Phase 3 Re-Spire study
- Dependence on single product YUTREPIA for near-term revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-058234 |
| Document: tm2614109d1_8k.htm | 0001104659-26-058234 |
| Document: tm2614109d1_ex99-2.htm | 0001104659-26-058234 |
| Document: 0001104659-26-058234-index-headers.html | 0001104659-26-058234 |
| Document: 0001104659-26-058234-index.html | 0001104659-26-058234 |
| Document: 0001104659-26-058234.txt | 0001104659-26-058234 |
| 8-K Data (Synthetic) | 0001104659-26-058234 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 12d ago | 8-K | $33.94 $34.78 | ▲ +2.48% | ▲ +2.19% | $43.74 (+28.87%) |
Oct 13, 2026 12d ago | Insider Cluster | $33.94 $34.78 | ▲ +2.48% | ▲ +2.19% | $43.74 (+28.87%) |
Sep 30, 2026 25d ago | 8-K | $27.99 $28.64 | ▼ −2.32% | ▼ −1.58% | $43.74 (−56.27%) |
Sep 3, 2026 7w ago | 8-K | $68.63 $68.66 | ▲ +0.04% | ▲ +0.43% | $43.74 (−36.27%) |
Sep 3, 2026 7w ago | Press Release | $68.63 $68.66 | ▲ +0.04% | ▲ +0.43% | $43.74 (−36.27%) |
Aug 25, 2026 8w ago | Insider Cluster | $71.36 $69.94 | ▼ −1.99% | ▼ −2.65% | $43.74 (−38.71%) |
Aug 21, 2026 9w ago | Insider Cluster | $70.27 $70.49 | ▲ +0.31% | ▼ −0.01% | $43.74 (−37.75%) |
Aug 12, 2026 10w ago | 8-K | $78.79 $72.10 | ▼ −8.49% | ▼ −9.19% | $43.74 (−44.49%) |
Aug 12, 2026 10w ago | Press Release | $78.79 $72.10 | ▲ +8.49% | ▲ +9.19% | $43.74 (+44.49%) |
Jul 29, 2026 12w ago | Insider Cluster | $86.80 $84.11 | ▼ −3.10% | ▼ −3.82% | $43.74 (−49.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers